Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,676 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type II Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

NCT01474018
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
QR-bromocriptine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

mHealth Intervention for Older Adults

NCT03398590
View directory record Official record
Conditions
Type2 Diabetes, Obesity
Interventions
self-regulation theory-based mHealth behavior intervention
Behavioral
Lead sponsor
Boston College
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Grains, Gastric Emptying and Glycemic Response

NCT03467659
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions
Cracked whole wheat porridge, Semolina wheat porridge, Whole wheat flour porridge, Refined wheat flour porridge, Refined wheat flour porridge,fine bran, Refined wheat flour porridge,coarse bran
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00432276
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin, Pioglitazone, Metformin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 9, 2026, 4:11 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 9, 2026, 4:11 PM EDT
Completed No phase listed Observational

A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes

NCT00717223
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

The Health Influences of Puberty (HIP) Study

NCT01775813
View directory record Official record
Conditions
Obesity, Insulin Resistance, Gonadal Dysfunction, Type 2 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

NCT00671424
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
Hydrochlorothiazide (HCTZ), Remogliflozin etabonate (GSK189075), Furosemide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional

Understanding and Optimizing Care for Young Adults With Type 1 and Type 2 Diabetes Mellitus Transitioning to Adult Care

NCT05229718
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Diabetes Collaborative Care Model for Young Adults, Usual Care Model
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 9, 2026, 4:11 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

NCT00085982
View directory record Official record
Conditions
Severe Insulin Resistance
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

NCT04537923
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Insulin Lispro (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

NCT01680341
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01407003
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 9, 2026, 4:11 PM EDT
Terminated No phase listed Observational

The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes

NCT01855386
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy
Interventions
Subjects with Gestational Diabetes, Controls without Gestational Diabetes
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

NCT04424888
View directory record Official record
Conditions
Diabetes Type 2, Diabetes Mellitus
Interventions
WB-011, Placebo, Continuous Glucose Monitor
Other · Device
Lead sponsor
Pendulum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

NCT02008942
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

NCT06628362
View directory record Official record
Conditions
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 4:11 PM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

NCT01765270
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)

NCT03403231
View directory record Official record
Conditions
Prediabetes
Interventions
INVENT Secure Messaging Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 75 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional

A Continuous Glucose Monitor Based Insulin Bolus Calculator

NCT05229445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
continuous glucose monitor based insulin bolus calculator
Device
Lead sponsor
Welldoc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 9, 2026, 4:11 PM EDT
Completed No phase listed Observational

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

NCT06914141
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
28,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 9, 2026, 4:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico

NCT02549495
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 9, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

NCT00365781
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS 113715
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Oct 9, 2026, 4:11 PM EDT